Genenta Science
Update in progressGNTA (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Genenta Science S.p.A. is a Milan‑based clinical‑stage biotechnology company focused on hematopoietic stem cell gene therapies for cancer. Its lead candidate, Temferon, is in Phase 1/2a trials for glioblastoma with unmethylated MGMT promoters. The company is also pursuing Temferon in other solid tumors and liver cancers, and developing a platform to deliver immunomodulatory molecules to tumors via monocytes/macrophages. Founded 2014.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.04
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!